ReviewNature reviews. Cancer2025
Metabolic interplays between the tumour and the host shape the tumour macroenvironment.
Review in Nature reviews. Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Cardiovascular-Kidney-Metabolic Syndrome, Healthy Lifestyles, and Risk of Cancer Incidence and Mortality: A Prospective Cohort Study.International journal of cancer · 2026Article
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- The use of blood test trends in cancer detection: a scoping review.Diagnostic and prognostic research · 2026Review
- Catalytic profiling of extracellular vesicles maps altered cancer metabolism.Nature nanotechnology · 2026Article
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study.Clinical pharmacology and therapeutics · 2026Article
- Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy.Cells · 2026Review
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Synergistic Probe Combining Lysosome Anchoring and Tumor Defense System Targeting for Precise Tumor Visualization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lactate-to-albumin ratio as an independent predictor of short- and long-term mortality in ICU patients with malignant tumors: A retrospective cohort study.Oncology letters · 2026Article
- Targeting the cancer metabolism-immunity interface: update and perspectives.Experimental hematology & oncology · 2026Review
- Predictive Value of Peripheral Blood Inflammatory Markers and Nutritional Indices for Survival in Young Patients with Advanced Non-Small Cell Lung Cancer: Construction of a Nomogram.Current oncology (Toronto, Ont.) · 2026Article
- Combined Pharmacologic and Nutritional Modulation of High-Fat Diet-Associated Tumor-Supportive Features in Prostate Cancer Models.Biomolecules · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- A Radioresistant-Tumor-Targeted Nanoparticle for X-Ray-Controlled Nitric Oxide Release to Potentiate Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Plasma proteome-metabolome signatures enable non-invasive early detection and lymph node risk stratification in breast cancer.Molecular cancer · 2026Article
- Article
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- HBx-mediated GPT2 suppression promotes liver cancer development by downregulating ADH1A.Cancer biology & medicine · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic reprogramming of cancer cells and the tumour microenvironment are pivotal characteristics of cancers, and studying these processes offer insights and avenues for cancer diagnostics and therapeutics. Recent advancements have underscored the impact of host systemic features, termed macroenvironment, on facilitating cancer progression. During tumorigenesis, these inherent features of the host, such as germline genetics, immune profile and the metabolic status, influence how the body responds to cancer. In parallel, as cancer grows, it induces systemic effects beyond the primary tumour site and affects the macroenvironment, for example, through inflammation, the metabolic end-stage syndrome of cachexia, and metabolic dysregulation. Therefore, understanding the intricate metabolic interplay between the tumour and the host is a growing frontier in advancing cancer diagnosis and therapy. In this Review, we explore the specific contribution of the metabolic fitness of the host to cancer initiation, progression and response to therapy. We then delineate the complex metabolic crosstalk between the tumour, the microenvironment and the host, which promotes disease progression to metastasis and cachexia. The metabolic relationships among the host, cancer pathogenesis and the consequent responsive systemic manifestations during cancer progression provide new perspectives for mechanistic cancer therapy and improved management of patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.